Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Correction: Imatinib Ameliorates Neuroinflammation in a Rat Model of Multiple Sclerosis by Enhancing Blood-Brain Barrier Integrity and by Modulating the Peripheral Immune Response.
A pilot, longitudinal, 24-week study to evaluate the effect of interferon beta-1a subcutaneous on changes in susceptibility-weighted imaging-filtered phase assessment of lesions and subcortical deep-gray matter in relapsing-remitting multiple sclerosis.
Platelets and vascular inflammation of the brain.
Asynchrony in Executive Networks Predicts Cognitive Slowing in Multiple Sclerosis.
MS14 Down-regulates Lipocalin2 Expression in Spinal Cord Tissue in an Animal Model of Multiple Sclerosis in female C57BL/6.
Correction: deep gray matter demyelination detected by magnetization transfer ratio in the cuprizone model.
MicroRNA in neurodegenerative drug discovery: the way forward?
Application of next-generation sequencing technologies in Neurology.
Differentiation and quantification of inflammation, demyelination and axon injury or loss in multiple sclerosis.
Oncostatin M protects against demyelination by inducing a protective microglial phenotype.
Cervical and ocular vestibular evoked myogenic potentials in multiple sclerosis participants.
Comparative efficacy of alemtuzumab and established treatment in the management of multiple sclerosis.
The Gender Gap in Multiple Sclerosis: Intersection of Science and Society.
Overexpression of CD44 in Neural Precursor Cells Improves Trans- Endothelial Migration and Facilitates Their Invasion of Perivascular Tissues In Vivo.
Epstein Barr virus is not a characteristic feature in the central nervous system in established multiple sclerosis.
Spasticity in multiple sclerosis: Associations with impairments and overall quality of life.
Immune-mediated processes in neurodegeneration: where do we stand?
Inhibition of Epidermal Growth Factor Receptor Improves Myelination and Attenuates Tissue Damage of Spinal Cord Injury.
The molecular physiology of the axo-myelinic synapse.
The poor recovery of neuromyelitis optica spectrum disorder is associated with a lower level of CXCL12 in the human brain.
Restless legs syndrome in multiple sclerosis.
XY sex chromosome complement, compared with XX, in the CNS confers greater neurodegeneration during experimental autoimmune encephalomyelitis.
Humoral responses to herpesviruses are associated with neurodegeneration after a demyelinating event: Results from the Multi-Center SET study.
Methods for identifying subject-specific abnormalities in neuroimaging data.
Protein 4.1R attenuates autoreactivity in experimental autoimmune encephalomyelitis by suppressing CD4(+) T cell activation.
Pages
« first
‹ previous
…
521
522
523
524
525
526
527
528
529
…
next ›
last »